Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study
Authors
Keywords
-
Journal
NEUROPSYCHOPHARMACOLOGY
Volume 42, Issue 4, Pages 844-853
Publisher
Springer Nature
Online
2016-09-29
DOI
10.1038/npp.2016.224
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants
- (2016) Robert M. Berman et al. CNS SPECTRUMS
- Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression
- (2015) D. Jeffrey Newport et al. AMERICAN JOURNAL OF PSYCHIATRY
- The Nature of Placebo Response in Clinical Studies of Major Depressive Disorder
- (2015) George I. Papakostas et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Word to the Wise About Ketamine
- (2014) Alan F. Schatzberg AMERICAN JOURNAL OF PSYCHIATRY
- Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?
- (2014) Gerard Sanacora et al. NEUROPSYCHOPHARMACOLOGY
- A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes
- (2014) A. McGirr et al. PSYCHOLOGICAL MEDICINE
- Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects
- (2013) G Sanacora et al. MOLECULAR PSYCHIATRY
- GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects
- (2013) Jeffrey Burgdorf et al. NEUROPSYCHOPHARMACOLOGY
- A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression
- (2012) Carlos A. Zarate et al. BIOLOGICAL PSYCHIATRY
- Correlation Between Different Levels of Placebo Response Rate and Clinical Trial Outcome in Major Depressive Disorder
- (2012) Nadia Iovieno et al. JOURNAL OF CLINICAL PSYCHIATRY
- Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications
- (2011) Ni A. Khin et al. JOURNAL OF CLINICAL PSYCHIATRY
- Antidepressant Response in Major Depressive Disorder: A Meta-Regression Comparison of Randomized Controlled Trials and Observational Studies
- (2011) Florian Naudet et al. PLoS One
- Antidepressant Drug Effects and Depression Severity
- (2010) Jay C. Fournier et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antidepressant–placebo differences in 16 clinical trials over 10 years at a single site: role of baseline severity
- (2010) Arif Khan et al. PSYCHOPHARMACOLOGY
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
- (2010) N. Li et al. SCIENCE
- The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder
- (2009) Ronald N. Marcus et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started